Suppr超能文献

肾活检实践:什么是金标准?

Renal biopsy practice: What is the gold standard?

作者信息

Brachemi Soumeya, Bollée Guillaume

机构信息

Soumeya Brachemi, Guillaume Bollée, Division of Nephrology and Research Center of the Centre Hospitalier de l'Université de Montréal and Université de Montréal, Montréal QC H2L 4M1, Canada.

出版信息

World J Nephrol. 2014 Nov 6;3(4):287-94. doi: 10.5527/wjn.v3.i4.287.

Abstract

Renal biopsy (RB) is useful for diagnosis and therapy guidance of renal diseases but incurs a risk of bleeding complications of variable severity, from transitory haematuria or asymptomatic hematoma to life-threatening hemorrhage. Several risk factors for complications after RB have been identified, including high blood pressure, age, decreased renal function, obesity, anemia, low platelet count and hemostasis disorders. These should be carefully assessed and, whenever possible, corrected before the procedure. The incidence of serious complications has become low with the use of automated biopsy devices and ultrasound guidance, which is currently the "gold standard" procedure for percutaneous RB. An outpatient biopsy may be considered in a carefully selected population with no risk factor for bleeding. However, controversies persist on the duration of observation after biopsy, especially for native kidney biopsy. Transjugular RB and laparoscopic RB represent reliable alternatives to conventional percutaneous biopsy in patients at high risk of bleeding, although some factors limit their use. This aim of this review is to summarize the issues of complications after RB, assessment of hemorrhagic risk factors, optimal biopsy procedure and strategies aimed to minimize the risk of bleeding.

摘要

肾活检(RB)对肾脏疾病的诊断和治疗指导很有用,但会引发不同严重程度的出血并发症风险,从短暂性血尿或无症状血肿到危及生命的出血。已确定了RB术后并发症的几个风险因素,包括高血压、年龄、肾功能下降、肥胖、贫血、血小板计数低和止血障碍。术前应仔细评估这些因素,并尽可能加以纠正。随着自动活检设备和超声引导技术的应用,严重并发症的发生率已降低,目前这是经皮肾活检的“金标准”操作。对于精心挑选的无出血风险因素的人群,可考虑门诊活检。然而,关于活检后观察时间的问题仍存在争议,尤其是对于自体肾活检。经颈静脉肾活检和腹腔镜肾活检是出血风险高的患者进行传统经皮活检的可靠替代方法,尽管一些因素限制了它们的使用。本综述的目的是总结肾活检后并发症的问题、出血风险因素的评估、最佳活检操作以及旨在将出血风险降至最低的策略。

相似文献

1
Renal biopsy practice: What is the gold standard?
World J Nephrol. 2014 Nov 6;3(4):287-94. doi: 10.5527/wjn.v3.i4.287.
3
Risk Factors for Severe Bleeding Complications in Percutaneous Renal Biopsy.
Am J Med Sci. 2017 Mar;353(3):230-235. doi: 10.1016/j.amjms.2016.12.019. Epub 2016 Dec 31.
4
Utility of transjugular renal biopsy as an alternative to percutaneous biopsy.
Nefrologia (Engl Ed). 2020 Nov-Dec;40(6):634-639. doi: 10.1016/j.nefro.2020.04.018. Epub 2020 Jul 11.
7
Safety of Kidney Biopsy when Performed as an Outpatient Procedure.
Kidney Blood Press Res. 2021;46(3):310-322. doi: 10.1159/000515439. Epub 2021 Jun 2.
8
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy.
Kidney Int. 2004 Oct;66(4):1570-7. doi: 10.1111/j.1523-1755.2004.00922.x.
9
Hemodynamic characteristics and the occurrence of renal biopsy-related arteriovenous fistulas in native kidneys.
Int Urol Nephrol. 2016 Oct;48(10):1667-73. doi: 10.1007/s11255-016-1411-z. Epub 2016 Aug 31.
10
Is it necessary to stop antiplatelet agents before a native renal biopsy?
Nephrol Dial Transplant. 2008 Nov;23(11):3566-70. doi: 10.1093/ndt/gfn282. Epub 2008 May 25.

引用本文的文献

1
Desmopressin and bleeding risk in high-risk native kidney biopsy: updated meta-analysis of RCTs and observational studies.
Ren Fail. 2025 Dec;47(1):2549775. doi: 10.1080/0886022X.2025.2549775. Epub 2025 Aug 31.
3
Technical and Institutional Factors Affecting Specimen Adequacy and Complications in Ultrasound-guided Kidney Biopsy: A Retrospective Cohort Study.
Can J Kidney Health Dis. 2025 May 6;12:20543581251336551. doi: 10.1177/20543581251336551. eCollection 2025.
6
Role of Desmopressin Acetate before Percutaneous Ultrasound-Guided Kidney Biopsy in Patients with Kidney Dysfunction.
Indian J Nephrol. 2024 May-Jun;34(3):228-232. doi: 10.4103/ijn.ijn_34_23. Epub 2023 Sep 29.
7
Exploring alternatives to laparoscopic renal biopsy: a critical examination of safety, efficacy, and costs.
Ren Fail. 2024 Dec;46(1):2343387. doi: 10.1080/0886022X.2024.2343387. Epub 2024 Apr 24.
8
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.
J Clin Med. 2024 Mar 25;13(7):1881. doi: 10.3390/jcm13071881.
9
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases.
Kidney Int Rep. 2023 Aug 14;8(11):2333-2344. doi: 10.1016/j.ekir.2023.07.037. eCollection 2023 Nov.
10
Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease.
Nephrol Dial Transplant. 2024 Feb 28;39(3):453-462. doi: 10.1093/ndt/gfad200.

本文引用的文献

1
Risk factors and timing of native kidney biopsy complications.
Nephron Extra. 2014 Mar 22;4(1):42-9. doi: 10.1159/000360087. eCollection 2014 Jan.
2
Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies.
Am J Nephrol. 2014;39(2):153-62. doi: 10.1159/000358334. Epub 2014 Feb 11.
3
Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010.
Clin J Am Soc Nephrol. 2012 Oct;7(10):1591-7. doi: 10.2215/CJN.02150212. Epub 2012 Jul 26.
4
Bleeding complications of native kidney biopsy: a systematic review and meta-analysis.
Am J Kidney Dis. 2012 Jul;60(1):62-73. doi: 10.1053/j.ajkd.2012.02.330. Epub 2012 Apr 24.
5
Development of an outpatient native kidney biopsy service in low-risk patients: a multidisciplinary approach.
Am J Nephrol. 2012;35(4):321-6. doi: 10.1159/000337359. Epub 2012 Mar 24.
7
Safety and predictors of complications of renal biopsy in the outpatient setting.
Clin Nephrol. 2011 Dec;76(6):464-9. doi: 10.5414/cn107128.
10
Experience with outpatient computed tomographic-guided renal biopsy.
Clin Nephrol. 2010 Dec;74(6):440-5. doi: 10.5414/cnp74440.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验